Big pharma is nearing important milestones in the race to develop and market the next blockbuster anti-inflammatory drug, gene therapies for Duchenne muscular dystrophy and new treatments for spinal muscular atrophy. Biotechs are looking for new treatments for nonalcoholic steatohepatitis, and three experimental therapies are vying to become the first gene therapy to cure hemophilia A.
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.